Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Asset Writedowns and Impairment (2019 - 2023)

Historic Asset Writedowns and Impairment for ImmunityBio (IBRX) over the last 5 years, with Q4 2023 value amounting to $886000.0.

  • ImmunityBio's Asset Writedowns and Impairment rose 3588.96% to $886000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $1.6 million, marking a year-over-year decrease of 8609.94%. This contributed to the annual value of $886000.0 for FY2023, which is 3353.34% down from last year.
  • Per ImmunityBio's latest filing, its Asset Writedowns and Impairment stood at $886000.0 for Q4 2023, which was up 3588.96% from $652000.0 recorded in Q4 2022.
  • ImmunityBio's Asset Writedowns and Impairment's 5-year high stood at $10.7 million during Q3 2020, with a 5-year trough of $40000.0 in Q4 2020.
  • Moreover, its 4-year median value for Asset Writedowns and Impairment was $724000.0 (2019), whereas its average is $2.6 million.
  • As far as peak fluctuations go, ImmunityBio's Asset Writedowns and Impairment tumbled by 9447.51% in 2020, and later surged by 3588.96% in 2023.
  • Over the past 4 years, ImmunityBio's Asset Writedowns and Impairment (Quarter) stood at $724000.0 in 2019, then tumbled by 94.48% to $40000.0 in 2020, then surged by 1530.0% to $652000.0 in 2022, then skyrocketed by 35.89% to $886000.0 in 2023.
  • Its Asset Writedowns and Impairment stands at $886000.0 for Q4 2023, versus $652000.0 for Q4 2022 and $40000.0 for Q4 2020.